Sector Imager 6000 Plate Reader

Sector Imager 6000 读板器

• 批准号: 8050230
• 负责人: JOHN C HUTTON
• 金额: $ 19万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-19 至 2012-08-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8050230
• 关键词: Animal Model; Autoantibodies; Autoimmune Diabetes; Autoimmune Diseases; Autoimmunity; Biological Assay; Biological Markers; Calibration; Centers for Disease Control and Prevention (U.S.); Childhood; Data; Detection; Diabetes Mellitus; Diagnosis; Disease; Environment; Funding; General Population; Goals; Grant; Housing; Human; Immunology; Individual; International; Investigational Therapies; Laboratories; Maintenance; Minor; Noise; Pathogenesis; Patients; Performance; Play; Quality Control; Radioisotopes; Reader; Reagent; Recruitment Activity; Risk; Role; Running; Scintillation Counter; Services; Signal Transduction; Societies; Speed; Standardization; Technology; Testing; Time; Translational Research; United States National Institutes of Health; Validation; cytokine; disease natural history; genetic analysis; instrument; micro-total analysis system; programs; research and development; research study; rituximab

DESCRIPTION (provided by applicant): The following proposal for the purchase of a Sector Imager 6000 Electrochemiluminescence plate reader is directed towards developing a high throughput shared facility for the analysis of immunological biomarkers of autoimmune disease and in particular autoantibodies and cytokines that play a role in the diagnosis and pathogenesis of type 1 autoimmune diabetes in humans. The Barbara Davis Center for Childhood Diabetes, where the instrument will be housed, is one of six reference laboratories in the world for the analysis of autoantibodies in new-diagnosed patients and for the identification of autoantibody positive individuals at risk of developing disease. The latter have been recruited into numerous national and international translational research studies following the natural history of the disease (DPT-1, TrialNet) and trails of experimental therapies (recently MMF, Rituximab, Bayhill). The SECTOR(R) Imager 6000 is extremely adaptable to a multiuser, multi-assay format without the need for calibration, resetting instrument parameters as well as being easily accessible compared to instruments such as scintillation counters and flow cytometers that are used in many of the current assays. It is now possible through the use of autoantibody testing combined with genetic analysis to identify individuals at risk of developing the disease from the general population however to achieve this goal there is a need to implement autoantibody assays using new formats that do not use radioisotopes yet can provide quantitative data that can be reproduced in multiple laboratories in very different operating environments all over the world. The MSD technology we contend is an excellent choice in that it brings us to the forefront of technology, yet provides a platform that is versatile and can be used for research and development of new assays and at the same time will be transplantable to fully-automated lab-on-a-chip assays that might ultimately be used as a point of service assay. Electrochemiluminescence detection affords distinct advantages in terms of speed, signal to noise and wide dynamic range over radiometric and photometric technologies. The ability to multiplex up to 10 analytes per well on prespotted plates is a significant saving in terms of reagents and operator time. The following proposal identifies a group of 4 major users involved in translational research and routine assay performance (70% instrument use) and 7 minor users (30% instrument use) who will principally use the machine for experimental research in animal models and in the research and development of new biomarkers of disease. Support from 20 NIH funded grants is documented ranging from several multicenter consortia to DERC pilot and feasibility grant holders. A plan for management and maintenance of the instrument is provided. Validation and quality control of the assays will be performed through our existing participation in the Diabetes Autoimmunity Standardization Program run from the Center of Disease control through the Immunology of Diabetes Society.

描述（由申请人提供）：以下购买Sector Imager 6000电化学发光酶标仪的提案旨在开发一种高通量共享设施，用于分析自身免疫性疾病的免疫学生物标志物，特别是在人类1型自身免疫性糖尿病的诊断和发病机制中发挥作用的自身抗体和细胞因子。Barbara Davis儿童糖尿病中心是世界上六个参考实验室之一，用于分析新诊断患者的自身抗体和识别有患病风险的自身抗体阳性个体。后者已被招募到许多国家和国际转化研究的疾病的自然史（DPT-1，TrialNet）和实验疗法（最近的MMF，利妥昔单抗，Bayhill）的踪迹。SECTOR（R）Imager 6000非常适合多用户、多检测格式，无需校准、重置仪器参数，并且与目前许多检测中使用的闪烁计数器和流式细胞仪等仪器相比，易于使用。现在可以通过使用自身抗体检测结合遗传分析来从普通人群中识别处于发展疾病风险的个体，然而为了实现这一目标，需要使用新的形式来实施自身抗体测定，所述新的形式不使用放射性同位素，但可以提供可以在全世界非常不同的操作环境中的多个实验室中再现的定量数据。我们认为MSD技术是一个很好的选择，因为它将我们带到了技术的最前沿，但提供了一个多功能的平台，可用于研究和开发新的检测方法，同时可移植到最终可能用作服务点检测的全自动芯片实验室检测方法中。电化学发光检测在速度、信噪比和宽动态范围方面优于辐射和光度技术。在预灌封板上每孔最多可复用10种分析物的能力在试剂和操作员时间方面是一个显著的节省。以下提案确定了4个主要用户（70%的仪器使用）和7个次要用户（30%的仪器使用），其中4个主要用户参与转化研究和常规测定性能，7个次要用户主要将机器用于动物模型的实验研究以及新疾病生物标志物的研究和开发。记录了20个NIH资助的赠款的支持，范围从几个多中心财团到DERC试点和可行性赠款持有人。提供了仪器的管理和维护计划。将通过我们目前参与的糖尿病自身免疫标准化计划（由疾病控制中心通过糖尿病免疫学协会运行）进行检测的验证和质量控制。